These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 9307267)
1. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267 [TBL] [Abstract][Full Text] [Related]
2. Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts. Chen ZP; Wang ZM; Carter CA; Alley MC; Mohr G; Panasci LC J Pharmacol Exp Ther; 2001 Mar; 296(3):712-5. PubMed ID: 11181897 [TBL] [Abstract][Full Text] [Related]
3. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937 [TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model. Chen ZP; Wang G; Huang Q; Sun ZF; Zhou LY; Wang AD; Panasci LC J Neurooncol; 1999 Aug; 44(1):7-14. PubMed ID: 10582663 [TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter. Chen ZP; Pan J; Huang Q; Sun ZF; Zhou LY; Wang AD J Neurooncol; 2001 Jan; 51(1):19-24. PubMed ID: 11349876 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells. Skalski V; Yarosh DB; Batist G; Gros P; Feindel W; Kopriva D; Panasci LC Mol Pharmacol; 1990 Sep; 38(3):299-305. PubMed ID: 2402223 [TBL] [Abstract][Full Text] [Related]
7. Intrathecal chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea encapsulated into hybrid liposomes for meningeal gliomatosis: an experimental study. Kitamura I; Kochi M; Matsumoto Y; Ueoka R; Kuratsu J; Ushio Y Cancer Res; 1996 Sep; 56(17):3986-92. PubMed ID: 8752168 [TBL] [Abstract][Full Text] [Related]
8. Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea. Kokkinakis DM; Moschel RC; Pegg AE; Schold SC Clin Cancer Res; 1999 Nov; 5(11):3676-81. PubMed ID: 10589786 [TBL] [Abstract][Full Text] [Related]
9. Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. Dolan ME; Fleig MJ; Feuerstein BG; Basu HS; Luk GD; Casero RA; Marton LJ Cancer Res; 1994 Sep; 54(17):4698-702. PubMed ID: 8062267 [TBL] [Abstract][Full Text] [Related]
10. The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man. Skalski V; Rivas J; Panasci L; McQuillan A; Feindel W Cancer Chemother Pharmacol; 1988; 22(2):137-40. PubMed ID: 3409444 [TBL] [Abstract][Full Text] [Related]
11. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways. Huynh H; Nguyen TH; Panasci L; Do P Cancer; 2004 Dec; 101(12):2881-91. PubMed ID: 15529313 [TBL] [Abstract][Full Text] [Related]
12. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU. Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. Cao S; McGuire JJ; Rustum YM Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100 [TBL] [Abstract][Full Text] [Related]
14. Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics. Noë AJ; Malapetsa A; Panasci LC Cancer Res; 1994 Mar; 54(6):1491-6. PubMed ID: 8137253 [TBL] [Abstract][Full Text] [Related]
15. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341 [TBL] [Abstract][Full Text] [Related]
16. Preclinical antitumor activity of bizelesin in mice. Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280 [TBL] [Abstract][Full Text] [Related]
17. Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats. Emerich DF; Winn SR; Bartus RT Cell Transplant; 2002; 11(1):47-54. PubMed ID: 12095219 [TBL] [Abstract][Full Text] [Related]
18. Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system. Noë AJ; Malapetsa A; Panasci LC Mol Pharmacol; 1993 Jul; 44(1):204-9. PubMed ID: 8341272 [TBL] [Abstract][Full Text] [Related]
19. Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model. Slagel DE; Feola J; Houchens DP; Ovejera AA Cancer Res; 1982 Mar; 42(3):812-6. PubMed ID: 7059979 [TBL] [Abstract][Full Text] [Related]
20. Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. Schold SC; Friedman HS; Bjornsson TD; Bigner DD Cancer Res; 1984 Jun; 44(6):2352-7. PubMed ID: 6722774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]